Release date: April 15, 2019
Expiration date: April 14, 2020
Estimated time to complete activity: 45 minutes
In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016).
Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016).
Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.
The target audiences for these activities are urologists, medical oncologists, urology/oncology nurses, advanced practice registered nurses and nurse navigators.
At the conclusion of these educational initiatives, participants should be able to:
- Use care-planning tools and resources to assess and document patient goals, preferences, and concerns, and to support shared decision-making during clinic visits.
- Describe common side effects associated with treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC).
- Apply best supportive care practices for treating adverse events associated with treatment for nmCRPC.
Mary W. Dunn, RN, MSN, OCN, NP-C
University of North Carolina Chapel Hill
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Medical Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. The maximum number of Pharmacotherapy contact hours awarded for Advanced Practice Registered Nurses is 0.6 contact hours.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related material that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Mary W. Dunn, RN, MSN, OCN, NP-C, has no real or apparent conflicts of interest to report.
Planners And Managers
The PIM planners and managers have nothing to disclose. The Carevive Systems, Inc. planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period April 15, 2019 through April 14, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 13920. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
Hardware and Software Requirement
- A computer with an internet connection
- A PDF viewing software: Adobe Acrobat Reader or Apple Preview
- Internet Browser: Latest versions of Internet Explorer, Firefox, Safari, or any other W3C standards compliant browser
- Additional Software: PowerPoint, Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/ or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
Grant funding provided by Astellas.